Rani Therapeutics Holdings (RANI) Other financing activities (2021 - 2026)
Rani Therapeutics Holdings (RANI) posted quarterly Other financing activities of $12000.0 for Q4 2025, up 125.0% year-over-year from $5333.3 in Q4 2024, and up 100.3% quarter-over-quarter from -$3.9 million in Q3 2025.
Rani Therapeutics Holdings (RANI) Other financing activities (2021 - 2026) Analysis & Trends
Rani Therapeutics Holdings' Other financing activities history runs 5 years deep, the most recent figure standing at $12000.0 for Q4 2025.
- In Q4 2025, Other financing activities rose 125.0% year-over-year to $12000.0; the TTM figure through Mar 2026 stood at $12000.0 (down 99.86% YoY), while the FY2025 annual figure was $12000.0, down 76.47% from the prior year.
- Other financing activities for Q4 2025 stood at $12000.0, up from -$3.9 million in the prior quarter.
- The five-year high for Other financing activities was $8.9 million in Q3 2024, with the low at -$3.9 million in Q3 2025.
- The 5-year median for Other financing activities is $13000.0 (2021), against an average of $595533.3.
- The sharpest annual moves came in 2023 and 2025: Other financing activities tumbled 369.39% in 2023, then soared 3353.72% in 2025.
- Rani Therapeutics Holdings' Other financing activities stood at -$13000.0 in 2021, then plunged by 1038.46% to -$148000.0 in 2022, then soared by 127.03% to $40000.0 in 2023, then slumped by 220.0% to -$48000.0 in 2024, then soared by 125.0% to $12000.0 in 2025.
- Business Quant data shows RANI's Other financing activities at $12000.0 in Q4 2025, -$3.9 million in Q3 2025, and $3.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Rani Therapeutics Holdings | 163.98 Mn | 163.98 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 57,000.00 |
| Jun 30, 2026 | 57,000.00 |
| Mar 31, 2026 | 5,000.00 |
| Mar 31, 2026 | 5,000.00 |
| Dec 31, 2025 | 12,000.00 |
| Dec 31, 2025 | 12,000.00 |
| Sep 30, 2025 | -3.94 Mn |
| Sep 30, 2025 | -3.94 Mn |
| Jun 30, 2025 | 3.94 Mn |
| Jun 30, 2025 | 3.94 Mn |
| Dec 31, 2024 | -48,000.00 |
| Dec 31, 2024 | -48,000.00 |
| Sep 30, 2024 | 8.88 Mn |
| Sep 30, 2024 | 8.88 Mn |
| Jun 30, 2024 | -121,000.00 |
| Jun 30, 2024 | -121,000.00 |
| Mar 31, 2024 | 121,000.00 |
| Mar 31, 2024 | 121,000.00 |
| Dec 31, 2023 | 40,000.00 |
| Dec 31, 2023 | 40,000.00 |